R&D Blueprint
The R&D Blueprint is a global strategy and preparedness plan that allows the rapid activation of research and development activities during epidemics. Its aim is to fast-track the availability of effective tests, vaccines and medicines that can be used to save lives and avert large scale crises.
Key actions by disease
Upcoming consultations
Useful resources
Accelerating R&D and Saving Lives
/photostory/2021-waaw-viet-nam/waaw-2021-viet-nam-photo-story-7.jpg?sfvrsn=12ba95bc_7 "A technician prepares a microscopic slide in a laboratory in Hanoi, Viet Nam")
Related activities
Online learning
All →/clinical-trials-for-new-re-emerging-pathogens-gpp-module-1.tmb-549v.png?sfvrsn=6d4247d9_1)
Documents
All →
4 April 2023
WHO Technical Advisory Group – candidate vaccine prioritization. Summary of the evaluations and recommendations...
To date four candidate vaccines have been evaluated at meetings that took place between 20th February and 30th March 2023. The TAG-CVP members...
30 March 2023
COVID-19 vaccine tracker and landscape
The COVID-19 vaccine tracker and landscape compiles detailed information of each COVID-19 vaccine candidate in development by closely monitoring their...
Mpox Vaccine Tracker: List of vaccine candidates in research & developmentSmallpox vaccines have currently have been repurposed and recommended for...
Mpox therapeutics tracker - List of therapeutics candidates in research & developmentTherapeutics, mainly antivirals developed against Smallpox, have...
Publications
All →
This large, international, randomized controlled clinical trial is designed to enable an expeditious, agile and concurrent evaluation of the benefits and...
10 April 2020
WHO R&D Blueprint COVID-19: Informal consultation on the potential inclusion of Favipiravir in a clinical...
There has been some suggestions for the inclusion of Favipiravir in the Solidarity trial.
Currently, there are no licensed vaccines for the prevention of COVID 19. While efforts continue to develop effective vaccines, it is pertinent to examine...
